Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.

Front Endocrinol (Lausanne) · 2023 · PMC10765518 · PMID 38179304

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Canagliflozin was also borderline significant when compared with empagliflozin [RR 0.90 (0.82–0.99)] and sotagliflozin [RR 0.85 (0.73–1.00)] (see Supplementary Table S4 ) Supplementary Figure S5C and Supplementary Table S3 show the probability of serious AEs of each SGLT2i.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.